Using Buspar for Depression: How the Treatment Works

Buspirone, sold under the brand name BuSpar, is an anti-anxiety medication that has found a second life as an add-on treatment for depression. It is not typically prescribed on its own to treat major depressive disorder, but when paired with a standard antidepressant, it can improve outcomes for people whose depression has not fully responded to first-line therapy. The story behind how buspirone ended up in the depression toolkit is more interesting than a straightforward approval, involving a large government-funded trial, a mechanism that complements common antidepressants, and a side-effect profile that actually helps undo problems those antidepressants cause.

How Buspirone Affects the Brain

Buspirone works by partially activating a specific serotonin receptor called 5-HT1A.¹ “Partial agonist” means it stimulates the receptor, but only partway. Think of it as turning a dial to medium rather than cranking it to full blast. This matters because 5-HT1A receptors sit in brain regions involved in mood regulation, and nudging them into moderate activity appears to have both anxiety-reducing and mood-lifting effects.

Once you swallow buspirone, your liver breaks it down primarily through an enzyme system called CYP3A4. One of its breakdown products, known as 1-PP, actually reaches higher concentrations in the brain than buspirone itself and may contribute to the drug’s effects.² The heavy reliance on CYP3A4 for metabolism is something to keep in mind, because other medications that speed up or slow down that enzyme can dramatically change how much buspirone actually reaches your bloodstream.³

In animal studies, buspirone has shown effects that go beyond simply activating a single receptor. It reduced stress hormone levels, boosted a brain growth factor called BDNF, and improved behavioral signs of depression in socially isolated rats, performing comparably to the well-known antidepressant fluoxetine (Prozac) on several measures.⁴ Animal results don’t automatically translate to humans, but they helped build the rationale for testing buspirone’s antidepressant potential in clinical trials.

The STAR*D Trial and Buspirone as an Add-On

The most influential evidence for buspirone in depression comes from the STAR*D study, a large government-funded trial that followed people with major depression through multiple treatment steps. When patients didn’t get better on the SSRI citalopram alone, one option was adding buspirone to see if it would push them into remission. The comparison group added bupropion (Wellbutrin) instead. The results were strikingly close: about 30 percent of people in both the buspirone and bupropion groups achieved remission on a clinician-rated scale, and response rates were similar as well.⁵

That finding was genuinely surprising. Bupropion is a well-established antidepressant in its own right, while buspirone had been thought of mainly as an anxiety drug. Showing comparable augmentation results put buspirone on the map as a legitimate depression strategy, and the comparison has been cited repeatedly as a reason to consider buspirone when an SSRI alone isn’t working.⁶

The picture gets more complicated when you look at placebo-controlled studies. Open-label trials of buspirone augmentation have generally looked promising, but in two placebo-controlled trials, buspirone helped more than half of participants yet failed to separate statistically from placebo, because the placebo group also improved at high rates. This is a common problem in antidepressant research: the placebo response in depression trials can be quite strong, making it hard for add-on treatments to prove superiority even when they are genuinely helpful. The STAR*D comparison with bupropion, which didn’t use a placebo arm, remains the most cited evidence in buspirone’s favor.

Does Severity Matter?

One of the more useful findings for clinicians comes from a randomized, placebo-controlled trial that added buspirone to ongoing SSRI treatment. Looking at the entire group of participants, buspirone didn’t significantly outperform placebo at the study’s endpoint. But among patients whose depression was more severe at the start, buspirone augmentation produced a meaningfully greater improvement than placebo.⁷ There was also a notable early effect: after just the first week of the add-on phase, the buspirone group showed significantly greater improvement on a standard depression rating scale compared to placebo.

This pattern, where buspirone augmentation seems to matter most for people with harder-to-treat depression, aligns with the STAR*D context. The patients in that trial had already failed to respond to a first-line SSRI. In practice, buspirone augmentation is rarely the first thing a clinician reaches for in mild depression. It tends to enter the conversation when someone has partially responded to an SSRI or SNRI but still has significant symptoms, particularly if anxiety is also in the picture.

When Depression and Anxiety Overlap

Depression and anxiety co-occur so frequently that treating one without addressing the other often leaves patients feeling only partially better. Buspirone has an inherent advantage here because it was originally developed and approved specifically for generalized anxiety disorder. When researchers studied patients who had both anxiety and mild depressive symptoms, buspirone improved depression scores alongside anxiety scores. Buspirone-treated patients saw roughly a six-point drop in depression ratings compared to about a three-and-a-half-point drop in the placebo group.⁸

A more recent observational study in Korea tracked patients with depressive disorders who also had prominent anxiety symptoms and were given buspirone alongside their existing antidepressant. Over 12 weeks, both anxiety and depression scores dropped substantially. Anxiety scores fell by about 10 points on average, and depression scores dropped by roughly 7 points.⁹ This doesn’t prove buspirone caused the improvement in depression on its own, since patients were already on antidepressants. But it does suggest that when anxiety is dragging down someone’s overall recovery from depression, adding buspirone can address both dimensions at once.

Fixing a Common Antidepressant Side Effect

One of the most practical reasons clinicians add buspirone to an SSRI has nothing to do with improving the antidepressant effect itself. SSRIs are notorious for causing sexual side effects, including reduced desire, difficulty with arousal, and trouble reaching orgasm. These side effects are a leading reason people stop taking their antidepressants, which obviously makes the depression worse. Buspirone has shown the ability to reverse these problems for a meaningful number of people.

In a controlled trial, roughly 58 percent of patients on SSRIs who added buspirone reported improvement in sexual function, compared to 30 percent in the placebo group. The researchers concluded that buspirone’s effect on sexual dysfunction appeared to be a direct reversal of the SSRI’s side effects rather than simply a mood improvement that made sex more appealing.¹⁰ Case reports have described the same pattern, with sexual dysfunction resolving after buspirone was added to ongoing SSRI therapy.¹¹

This dual benefit, helping with residual depression while also countering sexual side effects, is part of why buspirone augmentation remains popular despite its somewhat mixed placebo-controlled data. For patients who are tempted to quit their SSRI because of sexual problems, adding buspirone can keep them on the antidepressant that is helping their mood while restoring a quality-of-life issue that matters enormously to many people.

Buspirone in Older Adults

Depression in older adults often looks different and comes with additional challenges: cognitive decline, multiple medications, greater sensitivity to side effects. Buspirone has been studied in this population and the results are encouraging. In a controlled trial of patients over 65, buspirone at an average dose of about 18 mg per day significantly improved both anxiety and depression scores compared to placebo. It was equally effective whether the anxiety was a standalone diagnosis or secondary to depression. Side effects were mild and actually less common in the buspirone group than the placebo group.¹²

More recently, a randomized controlled trial tested adding buspirone to the SNRI venlafaxine in older adults who had depression accompanied by cognitive impairment. By 12 weeks, the combination group showed significantly greater reductions in depression scores than venlafaxine alone. Perhaps more interesting, cognitive function also improved significantly in the combination group. Side effects were comparable between groups, consisting mainly of dry mouth, dizziness, and fatigue.¹³ The cognitive improvement is particularly noteworthy because few add-on treatments for depression have shown that benefit in older patients.

Safety Profile and Drug Interactions

Buspirone’s safety record is one of its strongest selling points for depression augmentation. Unlike benzodiazepines, which are sometimes used for anxiety in depressed patients, buspirone does not cause sedation at typical doses, does not impair coordination, does not interact dangerously with alcohol in the same way, and does not lead to physical dependence. A head-to-head comparison with diazepam found that while both drugs reduced anxiety, diazepam produced greater withdrawal symptoms upon discontinuation. Buspirone showed no evidence of pharmacological dependence.¹⁴

That said, buspirone is not entirely free of interaction concerns. Because it works on serotonin receptors and is often added to SSRIs or SNRIs, there is a theoretical and occasionally observed risk of serotonin syndrome, a condition where too much serotonin activity causes agitation, rapid heart rate, muscle twitching, and in severe cases, dangerously high body temperature. Case reports have documented symptoms consistent with serotonin syndrome when buspirone was added to fluoxetine.¹⁵ In practice, this combination is widely used and serious reactions are rare, but it’s important to know the warning signs.

The CYP3A4 metabolism pathway creates another category of interactions. Drugs that strongly inhibit CYP3A4, such as certain antifungals and some antibiotics, can cause buspirone levels to build up in your system. Conversely, drugs that ramp up CYP3A4 activity, like the antibiotic rifampicin, can slash buspirone’s blood levels so dramatically that the drug essentially stops working.¹⁶ Even grapefruit juice inhibits CYP3A4 enough to affect buspirone levels. If you’re starting or stopping any medication while taking buspirone, it’s worth checking with your prescriber about potential interactions.

How Buspirone Compares to Other Augmentation Options

When an SSRI isn’t enough for depression, clinicians have several augmentation strategies to choose from. The most commonly studied options include adding bupropion, adding an atypical antipsychotic like aripiprazole or quetiapine, adding lithium, or adding buspirone. Each comes with a different trade-off between efficacy and side effects.

Atypical antipsychotics tend to show clearer separation from placebo in augmentation trials, but they bring more serious side-effect concerns: weight gain, metabolic changes, and movement disorders with long-term use. Lithium has decades of augmentation evidence behind it but requires blood monitoring and has a narrow window between an effective dose and a toxic one. Bupropion augmentation is roughly as effective as buspirone augmentation, as the STAR*D trial showed, but bupropion can increase anxiety in some people and carries a seizure risk at high doses. Buspirone’s advantage is its relatively clean side-effect profile: minimal weight gain, no sedation, no dependence, and that bonus of potentially reversing SSRI-related sexual dysfunction. The disadvantage is weaker placebo-controlled evidence for its antidepressant effect specifically.

For a patient who is partially responding to an SSRI and also struggles with anxiety or SSRI-induced sexual problems, buspirone augmentation addresses multiple issues simultaneously with a low risk of new side effects. For a patient with severe, treatment-resistant depression and no particular anxiety or sexual-dysfunction burden, a clinician might lean toward an option with stronger standalone evidence.

Emerging Research on Buspirone and Neurogenesis

One of the more intriguing lines of research involves pairing buspirone with melatonin. A study testing this combination found that neither buspirone nor melatonin alone showed antidepressant-like activity in preclinical models, but together they did. When the combination was then tested in people with major depression, it produced significant improvement on several clinical measures compared to placebo or buspirone monotherapy.¹⁷ The proposed explanation centers on neurogenesis, the brain’s ability to grow new neurons. Both buspirone and melatonin individually promote aspects of neurogenesis, and researchers have hypothesized that combining them may have a synergistic effect on new brain cell growth in regions involved in mood regulation.¹⁸

This is still early-stage research, and the clinical trial was exploratory rather than definitive. But it points to an interesting possibility: buspirone’s future in depression treatment may involve novel drug combinations that leverage its unique receptor profile in ways that weren’t envisioned when the drug was first approved for anxiety in 1986.¹⁹ For a medication approaching its fourth decade on the market, the fact that researchers are still discovering new potential applications speaks to how much about brain chemistry remains to be worked out.

What to Expect If You Start Buspirone

If your doctor adds buspirone to your antidepressant regimen, there are a few practical things worth knowing. First, buspirone takes time. Unlike benzodiazepines, which produce near-instant effects, buspirone needs one to three weeks of regular use before its full effects become apparent. Some people notice early improvement within the first week, as one trial showed, but others need to be patient. This lag time is actually similar to how SSRIs themselves work, so if you’ve waited weeks for an antidepressant to kick in before, the experience won’t be unfamiliar.

Buspirone is usually started at a low dose and gradually increased. Typical therapeutic doses for augmentation range from about 15 to 30 mg per day, split into two or three doses. Taking it consistently matters more than taking it at the exact same time, but sticking to a schedule helps maintain steady blood levels. And because of that CYP3A4 interaction with grapefruit, you’ll want to be consistent about whether you consume grapefruit products. Having a glass of grapefruit juice some days but not others can create unpredictable swings in how much active drug reaches your brain.

Side effects, when they occur, tend to be mild: dizziness, nausea, headache, and lightheadedness are the most commonly reported. These often diminish after the first week or two. Unlike many antidepressants and anti-anxiety medications, buspirone does not typically cause weight gain, drowsiness, or cognitive dulling. And if you and your doctor eventually decide to stop buspirone, you can generally taper off without the withdrawal symptoms that make discontinuing SSRIs or benzodiazepines difficult for many people.